Anticlastogenicity of two derivatives of 1,4-dihydroisonicotinic acid in mouse micronucleus test.
Effects of two derivatives of 1,4-dihydroisonicotinic acid (1,4-DHINA) against the monofunctional alkylating agent ethyl methanesulfonate (EMS) were studied in the micronucleus test in (CBA x C57Bl/6(j)) mice. Adult males and pregnant females were treated with an antimutagen (i.p.) and 12h later they were exposed to EMS (i.p.). The frequencies of micronucleated (MN) polychromatic erythrocytes (PCEs) in mouse bone marrow and foetal liver were analysed 6, 12, 18, 24, 30, 36, 48 or 24, 48 and 72 h after the mutagen injection. In adults, the maximum number of MNPCEs was observed 36 or 24h after the EMS administration. In foetuses, which were treated in a maternal organism, such peak was found at 24h. Pre-treatment of mice with the antimutagens 2,6-dimethyl-3,5-diethoxycarbonyl-4-(Na carboxylate)-1,4-dihydropyridine (DHP) and glutapyrone (GP) decreased the yield of MNPCEs in male bone marrow. Having been observed at a peak of MN induction, the anticlastogenic effect of DHP (1/10 LD(50) or 340 mg/kg) reached 30%. DHP at the doses of 0.5-1mM/kg did not affect the EMS-induced frequency of MNPCEs in bone marrow, whereas GP inhibited it at the similar millimolar concentrations. Simultaneously with maternal bone marrow, foetal liver cells were analysed for MNs in the transplacental test. The anticlastogenic effect of DHP (1/10 LD(50)) was found to be more prolonged and higher in females than in males and to average 50%, but this antimutagen was not efficient in foetuses. Both antimutagens did not change the polychromatic/normochromatic erythrocyte (PCE/NCE) ratio as compared with EMS action. Results presented indicate a peak of EMS-induced micronucleated cells in mouse bone marrow 24 or 36 h and in foetal liver 24h after animal treatment. Two 1,4-DHINA derivatives exhibited anticlastogenic activity in adults, but not in foetuses.
Goncharova
R
R
Institute of Genetics and Cytology, National Academy of Sciences, Akademicheskaya st. 27, 220072, Minsk, Belarus. antimut@biobel.bas-net.by
Zabrejko
S
S
Dalivelya
O
O
Kuzhir
T
T
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005314:Embryonic and Fetal Development / Q000187:drug effects; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects; D005020:Ethyl Methanesulfonate / Q000633:toxicity; D005260:Female; D007539:Isonicotinic Acids / Q000494:pharmacology*; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000196:embryology; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects; D008431:Maternal-Fetal Exchange; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D015162:Micronucleus Tests; D009153:Mutagens / Q000633:toxicity; D011247:Pregnancy
D016587:Antimutagenic Agents; D007539:Isonicotinic Acids; D009153:Mutagens; D005020:Ethyl Methanesulfonate